Medpace Holdings, Inc. to Post Q2 2022 Earnings of $1.30 Per Share, William Blair Forecasts (NASDAQ:MEDP)

Medpace Holdings, Inc. (NASDAQ:MEDPGet Rating) – Research analysts at William Blair lowered their Q2 2022 EPS estimates for shares of Medpace in a report released on Wednesday, April 27th. William Blair analyst J. Kreger now forecasts that the company will post earnings per share of $1.30 for the quarter, down from their previous estimate of $1.32. William Blair also issued estimates for Medpace’s Q3 2022 earnings at $1.40 EPS, Q4 2022 earnings at $1.48 EPS, FY2023 earnings at $6.59 EPS, FY2024 earnings at $7.76 EPS and FY2025 earnings at $9.28 EPS.

Medpace (NASDAQ:MEDPGet Rating) last announced its quarterly earnings data on Monday, April 25th. The company reported $1.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.43. Medpace had a net margin of 16.47% and a return on equity of 24.17%. The business had revenue of $330.90 million during the quarter, compared to analyst estimates of $327.09 million. During the same period last year, the firm posted $1.17 EPS. The company’s revenue was up 27.3% on a year-over-year basis.

MEDP has been the subject of several other reports. StockNews.com initiated coverage on Medpace in a report on Thursday, March 31st. They issued a “buy” rating for the company. Robert W. Baird boosted their price target on Medpace from $160.00 to $175.00 in a research note on Thursday, March 17th. Finally, Zacks Investment Research upgraded Medpace from a “hold” rating to a “buy” rating and set a $146.00 price target on the stock in a research note on Friday.

Shares of MEDP opened at $133.57 on Monday. Medpace has a 52-week low of $126.94 and a 52-week high of $231.00. The company has a market cap of $4.49 billion, a PE ratio of 24.92 and a beta of 1.48. The business has a fifty day moving average of $154.09 and a 200 day moving average of $182.76.

A number of large investors have recently modified their holdings of MEDP. Wellington Management Group LLP raised its position in Medpace by 602.9% in the 3rd quarter. Wellington Management Group LLP now owns 1,143,453 shares of the company’s stock valued at $216,433,000 after purchasing an additional 980,774 shares in the last quarter. Norges Bank acquired a new position in Medpace during the fourth quarter worth $57,343,000. Boston Trust Walden Corp raised its holdings in shares of Medpace by 38.2% in the first quarter. Boston Trust Walden Corp now owns 674,994 shares of the company’s stock worth $110,423,000 after acquiring an additional 186,518 shares during the last quarter. Loomis Sayles & Co. L P raised its holdings in shares of Medpace by 149.5% in the fourth quarter. Loomis Sayles & Co. L P now owns 233,242 shares of the company’s stock worth $50,763,000 after acquiring an additional 139,767 shares during the last quarter. Finally, Vulcan Value Partners LLC grew its position in shares of Medpace by 37.0% in the third quarter. Vulcan Value Partners LLC now owns 308,504 shares of the company’s stock valued at $58,394,000 after purchasing an additional 83,328 shares during the period. Institutional investors own 96.88% of the company’s stock.

About Medpace (Get Rating)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Further Reading

Earnings History and Estimates for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.